Search

Your search keyword '"Higgins, Mark"' showing total 596 results
Start Over Author "Higgins, Mark"
596 results on '"Higgins, Mark"'

229. Baxter Foods: a tradition of change

Author

Higgins, Mark

Subjects
Baxter Foods -- Management, Dairy industry -- Management, Business, Business, international, Food and beverage industries
Published
1997

230. Pinpointing production problems with NIR analysis

Author

Higgins, Mark

Subjects
Near infrared spectroscopy -- Usage, Pharmaceutical industry -- Equipment and supplies, Business, Business, international, Chemicals, plastics and rubber industries, Engineering and manufacturing industries
Published
1997

233. TO STAY ON GRID OR GO OFF GRID?

Author

Higgins, Mark

Subjects
ELECTRIC power distribution grids
Abstract

The article presents the insights of several executives whether people will stay on-grid or move into off-grid electrical systems including chief operating officer Mark Higgins of Strategen, managing director Simon Vardy and Simon Mezger of Australian Utilities of Accenture.

Published
2016

235. Tobramycin Inhalation Powder in Cystic Fibrosis Patients: Response by Age Group.

Author

Geller, David E., Nasr, Samya Z., Piggott, Simon, He, Ellie, Angyalosi, Gerhild, and Higgins, Mark

Subjects
AGE distribution, CONFIDENCE intervals, CYSTIC fibrosis, MEDICAL cooperation, PATIENT satisfaction, PSEUDOMONAS diseases, QUESTIONNAIRES, RESEARCH, RESEARCH funding, PULMONARY function tests, SPUTUM, STATISTICS, TOBRAMYCIN, DATA analysis, RANDOMIZED controlled trials, DESCRIPTIVE statistics, INHALATION administration, DISEASE complications
Abstract

BACKGROUND: Tobramycin powder for inhalation (TIP) is a drug-device combination designed to reduce treatment time and improve ease of use compared with tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients. However, the ability of patients to use dry powder inhalers, and the efficacy of the treatments, may vary by age. METHODS: The “Establish a New Gold Standard for Efficacy and Safety With Tobramycin in Cystic Fibrosis” (EAGER) trial was a randomized, 24-week, multicenter, open-label, parallel-group study designed to evaluate the safety of TIP versus TIS in 553 subjects, ages ≥ 6 years, with CF and P. aeruginosa infection. The main efficacy end point was percent-of-predicted FEV1 at week 20 (end of third cycle of treatment). A post hoc analysis was undertaken in 517 subjects who took ≥ 1 dose of study medication, to evaluate the relative efficacy and safety of TIP and TIS by age group: ≥ 6 to < 13 y (children, n = 46); ≥ 13 to < 20 y (adolescents, n = 114); and ≥ 20 y (adults, n = 357). RESULTS: Improvements in percent-of-predicted FEV1 from baseline to end of cycle 3 were greatest in the children for both TIP and TIS. The treatment differences (TIP − TIS) were 4.7% (85% CI −1.2 to 10.6), 3.7% (85% CI −0.1 to 7.5), and −0.8% (85% CI −3.1 to 1.5) in children, adolescents, and adults, respectively. Sputum P. aeruginosa density decreased from baseline with both treatments, with comparable treatment differences across the age groups after 3 cycles: children −0.93 (85% CI −2.4 to 0.5), adolescents −0.17 (85% CI −1.2 to 0.8), and adults −0.89 (85% CI −1.3 to −0.4). Overall, subject satisfaction scores were greater in all subjects with TIP, irrespective of age group. With the exception of cough and dysphonia, the safety profile of TIP was comparable to TIS, irrespective of age. CONCLUSIONS: TIP is comparable to TIS in efficacy outcomes and safety profile but had greater patient satisfaction in all the age groups. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

243. TV on DVD a strong sales driver if kept in check

Author

Higgins, Mark

Subjects
Television programs, Video recording industry, Video recordings, Video production companies, 20th Century Studios Inc.
Abstract

For all of our infinite wisdom, who could have ever anticipated that one of the strongest categories on DVD would be TV? I witnessed the power of TV on DVD [...]

Published
2006

246. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTRmutation: a double-blind, randomised controlled trial

Author

Moss, Richard B, Flume, Patrick A, Elborn, J Stuart, Cooke, Jon, Rowe, Steven M, McColley, Susanna A, Rubenstein, Ronald C, and Higgins, Mark

Abstract

Ivacaftor has been previously assessed in patients with cystic fibrosis with Gly551Asp-CFTRor other gating mutations. We assessed ivacaftor in patients with Arg117His-CFTR, a residual function mutation.

Published
2015
Full Text
View/download PDF

248. Going for Big Bucks

Author

Jones, Paul, McNeal, David, Hodgson, J., and Higgins, Mark

Abstract

The November '04 article "Going For Big Bucks" contains a glaring inaccuracy. On page 21, a quote reads, "A fellow named Mershon, a big dealer out of Ohio mainly known […]

Published
2005

250. Anonymous monolith brings a landmark movie to mind

Author

Higgins, Mark

Abstract

SEATTLE _ Rebecca Sargent gently put her fingertip to the black steel monolith mysteriously planted on a grassy knoll in Seattle's Magnuson Park and declared it had a vibe, like […]

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results